Zenas BioPharma, Inc.
NASDAQ:ZBIOBiotechnology
+$0.64 today
- Market cap
- $1.79B
- Beta
- -0.69
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$7.64
Volume 0.48M
Average 0.71M
ZBIO Income Before Tax
Profit after all operating and non-operating items but before income tax.
Zenas BioPharma, Inc.NASDAQ: ZBIO
Income Before Tax · Q1 FY2026 · quarter ended Mar 2026
Income before tax remains negative
Q1 FY2026 income before tax was -$80.99M, compared with -$33.78M a year earlier. Trailing-twelve-month income before tax was -$425.03M.
Context
- Income before tax amounted to 3778.2% of revenue in FY2025, up 647.0 pp from a year earlier.
- Income before tax grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly income before tax holds near -$80.99M or moves back toward the trailing-twelve-month quarterly average of -$106.26M.
Sources:Income StatementText generated from reported figures; not investment advice.
Income Before Tax history
USD · from the income statement
- Latest · FY2025
- (377.82M) USD
- Year-over-year change
- -141.3%
| Period | Period end | Income Before Tax | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (377.82M) | -141.3% |
| FY2024 | 2024-12-31 | (156.56M) | -325.2% |
| FY2023 | 2023-12-31 | (36.82M) | +69.1% |
| FY2022 | 2022-12-31 | (119.28M) | — |
Income Before Tax vs competitors
How ZBIO compares with its peers on the latest reported figures
- ZBIO's LTM Mar 2026 income before tax of -$425.03M is the 7th highest of the 8 companies compared; the peer median is -$156.76M.
- Its year-over-year change of -161.5% is the lowest of 8, against a peer median of -10.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $33.24M | +157.0% | — | 61.9% | |
| FY2025 | -$18.43M | -10.1% | — | — | |
| LTM Mar 2026 | -$69.66M | +46.5% | — | 832.6% | |
UPBUpstream Bio, Inc. | LTM Mar 2026 | -$156.76M | -98.0% | — | 4719.0% |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | -$166.09M | -1.5% | — | — |
| LTM Mar 2026 | -$196.48M | -17.4% | — | — | |
| LTM Mar 2026 | -$425.03M | -161.5% | — | — | |
| LTM Sep 2026 | -$510.25M | -10.3% | — | 7191.7% | |
| Peer median (excluding ZBIO) | -$156.76M | -10.1% | — | 2775.8% | |
Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 50M | 5M | 10M |
| Cost of Revenue | 61.69M | 0 | 139.14M | 0 |
| Gross Profit | (61.69M) | 50M | (134.14M) | 10M |
| Gross Margin | — | 100.0% | -2682.8% | 100.0% |
| Research & Development | 62.69M | 60.03M | 139.14M | 168.06M |
| Selling, General & Admin | 13.51M | 17.11M | 29.75M | 53.32M |
| Operating Expenses | 14.51M | 87.15M | 29.75M | 221.39M |
| Depreciation & Amortization | 78K | 113K | 137K | 56K |
| EBITDA | (75.12M) | (27.03M) | (156.42M) | (370.43M) |
| EBITDA Margin | — | -54.1% | -3128.4% | -3704.3% |
| Operating Income | (76.2M) | (37.15M) | (163.89M) | (211.39M) |
| Operating Margin | — | -74.3% | -3277.8% | -2113.8% |
| Interest Income | 0 | 0 | 0 | 12.15M |
| Interest Expense | 0 | 0 | 0 | 7.33M |
| Other Income / Expenses | (43.08M) | 324K | 7.33M | (166.43M) |
| Income Before Tax | (119.28M) | (36.82M) | (156.56M) | (377.82M) |
| Pre-Tax Margin | — | -73.6% | -3131.2% | -3778.2% |
| Income Tax Expense | 0 | 301K | 429K | (79K) |
| Net Income | (119.28M) | (37.12M) | (156.99M) | (377.74M) |
| Net Margin | — | -74.2% | -3139.8% | -3777.4% |
| EPS (Basic) | (3.11) | (0.97) | (3.76) | (8.44) |
| EPS (Diluted) | (3.11) | (0.97) | (3.76) | (8.44) |
| Weighted Avg Shares | 38.32M | 38.32M | 41.79M | 44.73M |
| Weighted Avg Shares (Diluted) | 38.32M | 38.32M | 41.79M | 44.73M |
Zenas BioPharma, Inc.
NASDAQ:ZBIO
Intrinsic Alpha fair value
Locked
Current Price
$26.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.